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meeting reporteeting report
the EMBO workshop on 
pre-mrNa processing and 
Disease took place between 
14 and 18 January 2007, 
in cortina d’ ampezzo, 
italy. it was linked to a 
satellite meeting focused on 
Mis-splicing and Disease, 
which received support 
from the European Network 
on alternative Splicing 
(EuraSNEt). these 
workshops were organized 
by t. Baralle, r. Luhrmann, 
F. pagani and J. Valcárcel.
Keywords: rNa 
processing; mrNa 
splicing; human disease
Introduction
gene expression is regulated extensively at the post-transcriptional 
level. the fundamental steps of eukaryotic rNa processing have 
been characterized in great detail, but knowledge of how the dis-
ruption of these processes contributes to human disease has only 
1MRC Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, UK 
2Cold Spring Harbor Laboratory, PO Box 100, Cold Spring Harbor, New York,  
New York 11724, USA 
3Laboratorio de Fisiología y Biología Molecular, Facultad de Ciencias Exactas y Naturales, 
Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, (C1428EHA) Buenos Aires, 
Argentina 
+Corresponding author. Tel: +44 (0)131 467 8426; Fax: +44 (0)131 467 8456;  
E-mail: javier.caceres@hgu.mrc.ac.uk 
++Corresponding author. Tel: +54 11 45763386; Fax: +54 11 45763321; 
E-mail: ark@fbmc.fcen.uba.ar 
Submitted 4 May 2007; accepted 12 June 2007; published online 13 July 2007
recently begun to emerge. this was the main theme of the EMBO 
Workshop on pre-mrNa processing and Disease held at cortina 
d’ampezzo, italy, in the magnificent surroundings of the Dolomites.
Alterations in general splicing factors and human disease
pre-messenger rNa (pre-mrNa) splicing is an essential step in 
eukaryotic gene expression. intron sequences are excised from pre-
cursor mrNas by the spliceosome, which is a large ribonucleoprotein 
complex composed of five small nuclear ribonucleoprotein particles 
(snrNps)—u1, u2, u4, u5 and u6—and more than 100 non-snrNp 
splicing factors. alternative splicing is an important mechanism for 
modulating gene expression and increases the proteomic complexity 
of a limited number of genes (reviewed by Matlin et al, 2005).
B. chabot (Sherbrooke, Quebec, canada) discussed the ori-
gin of introns in the genomes of higher eukaryotes. Bioinformatic 
analyses suggest that genomic duplication has been an impor-
tant mode of intron gain in mammals (zhuo et al, 2007). J. Beggs 
(Edinburgh, uK) presented evidence that in budding yeast the bio-
genesis of the u5 snrNp involves a cytoplasmic phase, and that 
the nuclear import of a u5-precursor complex is facilitated by a 
nuclear localization signal in prp8p (pre-mrNa processing fac-
tor 8; prpF8 in humans), a component of the u5 snrNp. curiously, 
defects in several ubiquitously expressed genes encoding consti-
tutive splicing factors, including prpF31, prpF3 and prpF8, are 
associated with autosomal-dominant retinitis pigmentosa (adrp). 
Beggs showed that adrp-associated mutations in the carboxyl 
terminus of human prpF8, when introduced into yeast prp8p, 
affect its interaction with the u5 snrNp protein, Brr2, and cause 
a defect in u5 snrNp maturation. J. Wu (chicago, iL, uSa) dis-
cussed an immunoprecipitation microarray method to identify 
transcripts associated with the splicing factor PRPF31. Several 
such transcripts were identified, in which splicing was inhibited by 
a prpF31 protein containing the identified adrp mutations. these 
results by Beggs and Wu highlight the importance of mutations in 
genes encoding general splicing factors in the aetiology of retinitis 
pigmentosa. proposed models of how mutations in general splic-
ing factors result in adrp pathogenesis are discussed in a recent 
review (see figure 3 in Mordes et al, 2006).
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approximately 15% of mutations that cause genetic diseases 
affect pre-mrNa splicing, and they often target conserved splic-
ing signals, including the 5' and 3' splice sites and the branch site 
(Krawczak et al, 1992). More recently, it has emerged that mutations 
in coding regions that were originally interpreted as silent single-
nucleotide polymorphisms, nonsense mutations that introduce pre-
mature stop codons, or missense mutations that cause amino-acid 
changes, can instead affect pre-mrNa splicing. Such mutations 
target cis-acting elements that influence exon recognition, either by 
disrupting or by creating exonic splicing enhancers and/or silencers 
(reviewed by pagani & Baralle, 2004).
t. Baralle (trieste, italy) described efforts to define new regu-
latory elements, known as composite exonic regulatory elements 
of splicing (cErES), in several disease-causing genes such as the 
cystic fibrosis gene, cystic fibrosis transmembrane conductance 
regulator (CFTR). these studies show that an exonic polymorphism 
cannot be ignored because it might affect the splicing process 
and lead to disease. this raises the issue of how functional splic-
ing assays can be included in genotype screenings to distinguish 
between polymorphisms and pathogenic mutations.
Ser/Arg-rich proteins in cancer and development
a. Krainer (cold Spring Harbor, Ny, uSa) reported that splicing 
factor, arginine/serine-rich 1 (SFRS1)—the gene encoding the pro-
totypical serine/arginine-rich (Sr) protein family member splicing 
factor 2/alternative splicing factor (SF2/aSF)—is a proto-oncogene. 
Various assays revealed that levels of SF2/aSF are elevated in dif-
ferent types of tumour. More importantly, SF2/aSF overexpression 
transforms immortal rodent cells and induces tumours in nude mice 
(Karni et al, 2007). another link between SF2/aSF and oncogenesis 
was discussed by g. Biamonti (pavia, italy), who described how 
SF2/aSF controls cell motility by affecting alternative splicing of the 
RON (macrophage stimulating 1 receptor (c-met-related tyrosine 
kinase)) proto-oncogene, leading to the production of the onco-
genic ∆ron isoform, which is found in breast and colon tumours 
(ghigna et al, 2005).
J. caceres (Edinburgh, uK) discussed the use of the ultraviolet 
crosslinking and immunoprecipitation (cLip) method (ule et al, 
2005) to identify nuclear and cytoplasmic mrNa targets of hetero-
geneous ribonucleoprotein (hnrNp) a1 and SF2/aSF. hnrNp a1 was 
found to bind to, and be necessary for, the processing of a micro-
rNa (mirNa) precursor, pre-mir-18a, which is part of the intronic 
oncogenic cluster mir-17-92. this finding underscores a new role for 
rNa-binding proteins as auxiliary factors that facilitate the process-
ing of specific mirNas (guil & caceres, 2007). an interesting link 
between Sr protein expression and a developmental process was 
provided by J. tazi (Montpellier, France). He reported that the Sr pro-
tein B52/Srp55 controls developmentally regulated splicing of eye-
less, a master gene of eye development in Drosophila. B52/Srp55 
controls the alternative splicing of exon 2, which leads to the pro-
duction of a protein isoform with an additional 60 amino acids and 
results in a small-eye phenotype. conversely, the canonical eyeless 
isoform induces eye overgrowth. thus, the splicing activity of B52/
Srp55 controls eye organogenesis and size (Fic et al, 2007).
More RNA targets for splicing regulators
identification of rNa targets of splicing regulators is crucial to 
understanding how alterations in splicing can result in human dis-
ease. a. Krämer (geneva, Switzerland) also used the cLip method to 
isolate rNa targets of the human splicing factor SF1 (also known as 
branch-point binding protein (BBp)) from HeLa cells. rNa interfer-
ence (rNai)-mediated depletion of SF1 affects the viability of human 
cells; however, it does not affect pre-mrNa splicing of several tested 
pre-mrNas (tanackovic & Kramer, 2005). this suggests that SF1 
might have a kinetic role in splicing, rather than being an essential 
splicing factor. analysis of the splicing of potential pre-mrNas tar-
gets in SF1-depleted HeLa cells indicates that SF1 is involved in the 
splicing of only certain introns and modulates alternative splice-site 
choice. J. Stévenin (illkirch, France) reported the identification of 
rNa targets of the testis-specific protein, rNa binding motif pro-
tein, y-linked, family 1 (rBMy)—an hnrNp protein that interacts 
with several well-known splicing regulators, such as the Sr proteins. 
In vitro selection (SELEX) experiments resulted in the identification of 
high-affinity binding targets for rBMy, consisting of rNa stem–loops 
capped by a pentaloop (Skrisovska et al, 2007).
the cross-regulation and functional redundancy between the 
splicing regulator polypyrimidine tract-binding protein (ptB) and 
its neuronal counterpart, nptB, was discussed by D. Black (Los 
angeles, ca, uSa) and c. Smith (cambridge, uK). ptB is an rNa-
binding protein that acts widely as a splicing repressor (reviewed 
by Spellman et al, 2005). in the brain, the closely related para-
logue, nptB, is specifically expressed in post-mitotic neurons, 
whereas ptB is restricted to glial and other non-neuronal cells. 
Smith discussed the use of two-dimensional difference gel electro-
phoresis (2D-DigE) to analyse the proteome of HeLa cells after 
rNai knockdown of ptB. He observed an increase in nptB—usu-
ally restricted to the neurons—which resulted from decreased 
skipping of nptB exon 10, a splicing pathway that leads to non-
sense-mediated decay (NMD). Simultaneous knockdown of both 
ptB and nptB led to large changes in alternative splicing of several 
model pre-mrNas, and numerous proteomic changes were 
accordingly observed using 2D-DigE. Black showed that the splic-
ing of a large group of exons is controlled during neuronal devel-
opment by a switch in expression between ptB and nptB, which 
display a mutually exclusive pattern of expression in the brain. the 
use of splicing-sensitive microarrays to identify different sets of 
exons regulated by ptB, nptB or both proteins, revealed that the 
splicing of these exon sets is altered during neuronal differentia-
tion, as predicted from the observed changes in ptB and nptB 
expression (Fig 1). therefore, the post-transcriptional switch from 
ptB to nptB induces a widespread alternative-splicing programme 
during neuronal development (Boutz et al, 2007).
J. ule (cambridge, uK) discussed biochemical and computa-
tional approaches to derive an rNa map describing the rules by 
which Nova, a neuron-specific rNa-binding protein, regulates alter-
native splicing. the rNa map relates the position of Nova-binding 
sites (ycay clusters) in a pre-mrNa to the outcome of splicing, and 
is able to predict the action of Nova (ule et al, 2006).
M. carmo-Fonseca (Lisbon, portugal) described microarray stud-
ies analysing the expression levels of 181 splicing-related genes 
across different tissues and biological processes. the genes that were 
specifically up- or downregulated in a particular tissue included 
those for well-known rNa-binding proteins, such as members of the 
hnrNp and Sr protein families, Sr protein kinases, DEaD-box rNa 
helicases and tissue-specific splicing regulators, and also several 
core snrNp components. robust signatures were associated with 
testis and whole brain, which are two organs with a high percentage 
of expressed genes that undergo alternative splicing.
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a. Bindereif (giessen, germany) showed that a ca-rich element 
in intron 13 of the nitric oxide synthase gene acts as a length-
dependent splicing enhancer that binds to hnrNp L. Exon micro-
array analysis identified genes in which hnrNp L acts either as an 
activator or as a repressor of various pre-mrNa processing events, 
including intron retention, exon skipping and poly(a)-site selection.
the Drosophila splicing regulator Sex-lethal (SXL) is expressed 
exclusively in female flies and regulates female-specific alterna-
tive splicing of at least three target genes: transformer (tra), male- 
specific-lethal 2 (msl-2) and sxl itself (reviewed by Forch & 
Valcárcel, 2003). J. Valcárcel (Barcelona, Spain) described micro-
array studies in flies that revealed widespread sex-specific changes 
in alternative splicing when comparing approximately 3,000 alter-
natively spliced genes in males and females. Several of these genes 
with sex-specific alternative splicing contain SXL-binding sites. 
Expression of SXL in male S2 cells resulted in partial recapitulation 
of the changes observed in the microarray studies.
Coupling and connections
Several talks at the meeting provided information on the connections 
between transcription and splicing. the transcription factor ca150—
also known as transcription elongation regulator 1 (tcErg1)—
localizes to nuclear speckles and is associated with factors involved 
in transcriptional elongation and splicing (Sanchez-alvarez et al, 
2006). M. garcía-Blanco (Durham, Nc, uSa) described a small 
interfering rNa (sirNa)-mediated ca150 knockdown approach fol-
lowed by gene expression analysis to identify its cellular targets. He 
identified high-confidence ca150 targets, and chromatin immuno-
precipitation (chip) analysis revealed ca150 occupancy of target 
gene loci, suggesting a direct effect on gene expression. c. Suñé 
(granada, Spain) described the presence of ca150 in transcription 
pre-initiation and elongation complexes isolated in vitro, which 
should allow a biochemical understanding of how the interactions 
that occur during elongation affect alternative splicing events.
N. proudfoot (Oxford, uK) extended the evidence for the for-
mation of loops that join together the promoter and the 3' end of 
genes (g-loops), originally found in yeast (O’Sullivan et al, 2004), 
to mammalian cells. J. Kjems (aarhus, Denmark) provided evi-
dence that splicing events in human immunodeficiency virus-1 
(HiV-1) can feed back and affect transcription of the viral genes. 
the failure of u1 snrNa to stably recognize a mutated 5' splice 
site inhibits transcriptional initiation by decreasing the recruit-
ment of the general transcription factor tFiiH and of the tata-
binding protein. a. Kornblihtt (Buenos aires, argentina) presented 
two non-exclusive mechanisms that couple polymerase (pol) ii 
transcription with alternative splicing. in the kinetic-coupling 
mechanism, the rate of pol ii elongation determines a time period 
of opportunity for the splicing machinery to recognize and dif-
ferentially use nascent splice sites. this mode was confirmed by 
using a slow mutant of pol ii that promotes the inclusion of a cas-
sette exon into the mature mrNa. Fluorescence recovery after 
photobleaching (Frap) experiments, performed in collaboration 
with E. Bertrand (Montpellier, France), confirmed that the pol ii 
mutant is indeed slow in vivo. in the recruitment-coupling mecha-
nism, the c-terminal domain of pol ii seems to have a crucial role 
by mediating an inhibitory effect of the Sr protein Srp20 on the 
inclusion of a cassette exon in an elongation-independent manner 
(de la Mata & Kornblihtt, 2006).
Towards corrective therapy
Spinal muscular atrophy is a neurodegenerative disorder caused 
by the deletion or mutation of the survival-of-motor-neuron gene 
(SMN1). all affected individuals carry a nearly identical SMN2 
gene paralogue, which differs by a c to t transition in exon 7 
that results in the skipping of this exon. Several strategies have 
been pursued to increase the extent of SMN2 exon 7 inclusion. 
J. Marquis (Bern, Switzerland) described the use of bifunctional 
antisense molecules that tether SF2/aSF-binding sites to exon 7 
through the antisense moiety (Skordis et al, 2003). to express 
these bifunctional rNas in cells, Marquis and D. Schumperli 
(Bern, Switzerland) used vectors based on u7 snrNp. By changing 
the antisense sequences they targeted different regions of exon 7, 
to maximize the extent of its inclusion.
S. Stamm (Erlangen, germany) addressed the connections 
between alternative splicing and signal transduction pathways by 
defining the roles of protein phosphatase 1 (pp1). this enzyme binds 
to a phylogenetically conserved rVDF sequence in the splicing factor 
transformer2-β1(tra2-β1), which is also present in eight other proteins, 
including SF2/aSF and Srp30c. pp1 dephosphorylates these proteins 
and influences their activities in splice-site selection. in particular, 
inhibition of pp1 promotes inclusion of SMN2 exon 7, which suggests 
that reducing pp1 activity could be a new therapeutic strategy to treat 
spinal muscular atrophy.
Duchenne muscular dystrophy is an X-linked myopathy caused 
by deletions and point mutations in the dystrophin gene, some of 
which induce premature termination codons giving rise to NMD. 
importantly, internal in-frame deletions in the dystrophin protein can 
be tolerated as they produce only mild myopathic symptoms; there-
fore, inducing exon skipping can be used as a therapeutic approach. 
Fig 1 | Mutually exclusive pattern of expression of PTB and nPTB in the brain. 
PTB and nPTB have different positive and negative effects on the splicing of 
many exons, some of which overlap between the two factors (represented by the 
Venn diagram on the right). Figure kindly provided by P. Boutz, P. Stoilov and 
D. Black. NMD, nonsense-mediated decay; PTB, polypyrimidine tract-binding 
protein; nPTB, neuronal PTB. 
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i. Bozzoni (rome, italy) showed that in vivo stable expression of con-
structs encoding the spliceosomal u1 snrNa—modified such that 
its 5' terminus is replaced by sequences complementary to the splice 
sites of the exon to be skipped—proved successful in rescuing both 
dystrophin synthesis and muscle function in the mdx mouse model of 
Duchenne muscular dystrophy (Denti et al, 2006).
c. Branlant (Nancy, France) described how the repressor protein 
hnrNp a1 competes with the Sr proteins Srp40 and Sc35, but not 
with SF2/aSF, for binding to selected regions of HiV-1 rNa to reg-
ulate splice-site selection in the generation of viral mature mrNas. 
conversely, M. caputi (Boca raton, FL, uSa) described how members 
of the hnrNp H family of proteins assemble in a multiple complex on 
the HiV-1 genome to correctly regulate viral replication, splicing and 
the export of more than 40 viral mature mrNas.
Connections to the clinic
the fibronectin gene undergoes extensive alternative splicing in 
three regions, generating up to 20 variants in humans. in particular, 
the alternatively spliced exon extra-domain a (EDa, also referred as 
EDi) has been extensively studied. E. White (ann arbor, Mi, uSa) 
reported that the EDa isoform is necessary for the development of 
pulmonary fibrosis, inducing the differentiation of myofibroblasts 
by an integrin-dependent mechanism. He reported that the phos-
phatase and tensin homologue (ptEN) signalling pathway blocks 
EDa exon inclusion through an unknown mechanism and prevents 
lung fibrosis, and that, conversely, patients with pulmonary fibrosis 
show decreased ptEN expression and increased EDa inclusion.
One of the aims in understanding global changes in alternative 
splicing associated with disease or triggered by external signals is 
to develop robust microarray systems that detect changes in mrNa 
isoform abundance with high sensitivity and reproducibility. 
a. Watkins (High Wycombe, uK) from affymetrix presented both 
the system and the software developed by this company. in contrast 
to other systems that are based on exon–exon junction oligonucleo-
tide probes, their alternative-splicing chip relies on exon-specific 
oligonucleotide probes.
r. tupler (Modena, italy) described the identification of FRG1 
overexpression as the cause of facioscapulohumeral muscular dys-
trophy (FSHD). FSHD patients carry deletions of several repeats 
that act as silencers of transcription of the FRG1 gene. this results in 
overexpression of FRG1, which encodes a spliceosome-associated 
protein. a transgenic-mouse model overexpressing FRG1 in skeletal 
muscle recapitulated the muscular dystrophy phenotype (gabellini 
et al, 2006). interestingly, specific pre-mrNas undergo aberrant 
alternative splicing in the muscle tissue of Frg1 transgenic mice 
and also in FSHD patients.
two talks dealt with splicing defects in membrane channels that 
cause ‘channelopathies’. L. crotti (pavia, italy) described mutations 
affecting splicing of the HERG (potassium voltage-gated channel, 
subfamily H (eag-related), member 2) and SCN5A (sodium chan-
nel, voltage-gated, type V, α-subunit) genes that cause Long Qt 
syndrome, which is an electrical disorder responsible for sudden 
cardiac death. g. Woods (cambridge, uK) found that mutations 
generating new splice variants in the α-subunit of the voltage-gated 
sodium channel ScN9a cause congenital insensitivity to pain (cox 
et al, 2006). c. Lazaro (Barcelona, Spain) and D. Baralle (cambridge, 
uK) discussed the importance of rNa analysis in the identification 
of the molecular defects associated with mutations in the neurofi-
bromin 1 (NF1) gene that cause type-i neurofibromatosis. Lazaro 
presented a study of 374 NF1 mutations, which revealed that 44% 
could be attributed to splicing defects. Baralle showed how a single 
point mutation in NF1 intron 31 generates a new 3' splice site leading 
to the inclusion of a cryptic exon in the mature mrNa. By using 
mutant minigenes transfected into mammalian cells in culture, she 
defined the cis- and trans-acting determinants of the pathological 
exonization within intron 31.
F. pagani (trieste, italy) studied a mutation that results in the 
expansion of a gaa triplet in frataxin intron 1, which causes 
Friedreich ataxia. By using a hybrid-minigene assay, he showed that 
the repeat expansion does not affect transcription; however, it induces 
aberrant splicing in a position-dependent manner, producing both 
exon-skipping and intron-retention forms of the mrNa. M. amaral 
(Lisbon, portugal) described mutations in the CFTR gene that cause 
cystic fibrosis by generating premature stop codons and triggering 
NMD. She proposed the use of aminoglycoside antibiotics that inhibit 
NMD as a therapeutic approach. i. Vorechovsky (Southampton, uK) 
addressed the links between splicing and complex trait diseases—that 
is, diseases caused by changes in multiple genes and that have a clear 
environmental component—such as type 1 diabetes and juvenile 
obesity, which are influenced by the susceptibility locus insulin-
dependent diabetes mellitus 2 (IDDM2) comprising the insulin gene. 
He showed examples of single-nucleotide polymorphisms in 
intron 1 of the insulin gene that generate new splicing isoforms 
and are associated with type 1 diabetes.
Perspectives
the meeting in cortina d'ampezzo provided numerous examples 
of mutations in cis-acting sequences and trans-acting factors that 
affect pre-mrNa splicing of genes important for human disease. 
interestingly, it became evident that mutations in genes encod-
ing general splicing factors might cause specific human diseases, 
such as adrp and spinal muscular atrophy, instead of producing 
pleiotropic defects. another important concept emerging from 
rNa analysis is that mutations in coding regions should not neces-
sarily be assumed to be silent single-nucleotide polymorphisms or 
the cause of single amino-acid changes, but could instead mark-
edly affect splicing and lead to human disease; this should be taken 
into account during genotype screenings. More importantly, there 
is now evidence that the accumulated basic knowledge is slowly 
but steadily translating into molecular therapies designed to correct 
defective pre-mrNa processing.
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